The biochemistry — ubiquinone, ubiquinol, and Complex III
Coenzyme Q10 (CoQ10, ubiquinone-10) is a lipid-soluble electron carrier in the mitochondrial inner membrane. The molecule consists of a benzoquinone head group with two methoxy substituents and a 10-isoprenoid tail (giving rise to the ‘Q10’ designation; shorter-tail CoQ analogues exist in other species — CoQ9 in mice, CoQ6 in yeast). Per Bhagavan 2006 (Free Radic Res) coenzyme Q10 review, the redox-active head group cycles between three oxidation states during normal cellular function: ubiquinone (fully oxidized, quinone form with two carbonyls), ubisemiquinone (one-electron reduced radical intermediate), and ubiquinol (fully reduced, hydroquinone form with two hydroxyls).
The electron-carrying function in the mitochondrial electron transport chain (ETC) works as follows: Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) transfer electrons from NADH and FADH2 respectively to ubiquinone, reducing it to ubiquinol. Ubiquinol diffuses through the inner-membrane lipid phase to Complex III (cytochrome bc1 complex), which re-oxidizes ubiquinol back to ubiquinone while passing electrons to cytochrome c. The continuous interconversion between ubiquinone and ubiquinol drives the proton gradient that powers ATP synthesis at Complex V (ATP synthase). Per the chemiosmotic theory of Mitchell 1979, this electron-transport-coupled proton pumping is the central energy-transduction mechanism of aerobic life. CoQ10 is the only mobile electron carrier between Complex I/II and Complex III, making it absolutely essential for mitochondrial ATP production.
Supplemental bioavailability — Hosoe 2007 ubiquinol PK study
Per Hosoe 2007 (Regul Toxicol Pharmacol) pharmacokinetic study comparing oral ubiquinol and ubiquinone in healthy human volunteers, ubiquinol produced approximately 2–3× higher plasma CoQ10 elevation than ubiquinone at equivalent doses. The proposed mechanism is that the reduced ubiquinol form has higher partition coefficient into intestinal enterocyte membranes than the oxidized ubiquinone form, allowing more efficient uptake from the gut lumen. Once absorbed, both forms enter the systemic CoQ10 pool because in-vivo interconversion is rapid — the bioavailability advantage of ubiquinol is at the absorption step, not at the in-vivo activity step.
The canine-specific pharmacokinetic data are sparse. The mechanistic basis (intestinal enterocyte uptake of reduced vs oxidized CoQ10) is conserved across mammals, supporting an a-priori expectation that the human PK advantage extends to dogs. The clinical-outcome significance is not specifically established for dogs eating CoQ10-fortified diets or receiving CoQ10 supplementation for cardiac indications. For practical formulator and owner decisions, ubiquinol is the bioavailability-preferred form when available; ubiquinone remains common in commercial pet food and supplement formulations because it is more stable under processing and storage conditions (ubiquinol oxidizes to ubiquinone on air exposure unless protected) and is meaningfully cheaper. See our CoQ10 explainer for the broader CoQ10 context and supplementation framing.
ACVIM 2022 nutritional cardiomyopathy adjunct — cardiac context only
Per ACVIM 2022 nutritional cardiomyopathy consensus and Freeman 2010 (JVIM) canine cardiac-nutrition review, CoQ10 is positioned as an adjunctive cardiac-support supplement for dogs with diet-associated cardiomyopathy (the FDA-CVM DCM context per Updates 1-3, 2018-2022) or specific cardiomyopathies with mitochondrial involvement. The mechanistic rationale is that cardiac muscle has among the highest mitochondrial density and ATP-production demand of any tissue, and supplemental CoQ10 may support mitochondrial energy production in failing or compromised cardiac muscle.
The canine cardiac-specific evidence base is smaller than for the parallel human cardiology applications but the mechanistic foundation is solid. Per ACVIM 2022, the consensus positioning is that CoQ10 alongside taurine (see our taurine explainer), L-carnitine (see our L-carnitine explainer), and marine omega-3 (see our omega-3 fatty acids explainer) constitutes a reasonable nutritional adjunct package for dogs with diet-associated DCM or other cardiomyopathies, layered onto whatever pharmacologic management (pimobendan, ACE inhibitors, diuretics) the veterinary cardiologist prescribes. See best dog food for heart disease for the broader clinical-context framework.
Healthy-dog routine supplementation — not supported
CoQ10 is not on the AAHA 2022 Pain Management Guidelines list of evidence-strong nutraceuticals for canine osteoarthritis, nor on the AAHA 2018 Senior Care Guidelines list of evidence-strong supplements for canine cognitive or age-related decline. Routine CoQ10 supplementation in healthy dogs is not supported by current canine evidence. Healthy dogs eating AAFCO-compliant complete diets do not require CoQ10 supplementation — canine tissues synthesize CoQ10 endogenously from tyrosine and mevalonate via the same biosynthetic pathway as humans (the pathway is partly shared with cholesterol biosynthesis and is consequently affected by statins in human cardiology).
The clinical-decision framework for owners is therefore: (1) CoQ10 supplementation in healthy dogs is not supported by evidence and is not necessary; (2) CoQ10 supplementation in dogs with veterinarian-confirmed cardiomyopathy or specific mitochondrial-energy indication is a reasonable adjunct per ACVIM 2022 framework, coordinated with the prescribing veterinarian; (3) when supplementation is chosen, ubiquinol is the bioavailability-preferred form per Hosoe 2007 PK data, while ubiquinone remains common in commercial products for stability and cost reasons. Dogs with confirmed cardiomyopathy should not have owners initiate CoQ10 supplementation outside the prescribing cardiologist’s direction — the supplement is layered onto medical management, not a substitute for it.
How KibbleIQ scores CoQ10 forms
The KibbleIQ Dry Kibble Rubric awards bioavailability credit when ubiquinol is declared on the ingredient list, versus ubiquinone, per the Hosoe 2007 PK evidence. The rubric does not penalize ubiquinone presence — both forms are AAFCO 2024-compliant and either may legitimately appear in commercial pet food. The credit reflects the consistent rubric pattern of recognizing bioavailability advantages of organic / reduced / chelated forms over inorganic / oxidized / oxide-salt forms (see our manganese explainer, selenium explainer, and zinc supplements explainer for parallel mineral-form bioavailability framing).
CoQ10 itself is not a baseline AAFCO-compliance requirement — AAFCO 2024 dog food nutrient profiles do not specify a CoQ10 minimum. CoQ10 presence in pet food labels is therefore a premium-formulation signal rather than a compliance requirement, and the form specification (ubiquinol vs ubiquinone) is a quality detail rather than a category-defining feature. The clinical relevance of CoQ10 supplementation runs through veterinary cardiology, not through pet food choice for healthy dogs. See best dog food for heart disease for the cardiac-context recommendation framework. To check whether your dog’s food declares CoQ10 (ubiquinol or ubiquinone), paste the ingredient list into the KibbleIQ analyzer.